PDF4PRO ⚡AMP

Modern search engine that looking for books and documents around the web

Example: biology

CONTRAINDICATIONS--------------------------

HIGHLIGHTS OF PRESCRIBING INFORMATIONT hese highlights do not include all the information needed to use vidaza safely and effectively. See full prescribing information for vidaza . vidaza (azacitidine for injection), for subcutaneous or intravenous useInitial Approval: 2004---------------------------RECENT MAJOR CHANGES---------------------------Dosage and Administration ( )7/2018----------------------------INDIC ATIONS AND USAGE--------------------------- vidaza is a nucleoside metabolic inhibitor indicated for the treatment of patients with the following FAB myelodysplastic syndrome (MDS) subtypes: Refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL). (1)----------------------DOSAGE AND ADMINISTRATION----------------------- The recommended starting dose for the first treatment cycle, for all patients regardless of baseline hematology values, is vidaza 75 mg/m2daily for 7 days to be administered by subcutaneous injection or intravenous infusion.

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use VIDAZA safely and effectively. …

Loading..

Tags:

  Vidaza

Information

Domain:

Source:

Link to this page:

Please notify us if you found a problem with this document:

Spam in document Broken preview Other abuse

Transcription of CONTRAINDICATIONS--------------------------

Related search queries